SPXN:NYE-ProShares S&P 500 ex-Financials ETF

ETF | Drug Manufacturers | NYE

Last Closing Price

USD 61.21


-0.12 (-0.19)%

Market Cap

USD 2.12M

Average Target Price

Average Analyst Rating


STA Verdict



The investment seeks investment results, before fees and expenses, that track the performance of the S&P 500® Ex-Financials and Real Estate Index (the index). Under normal circumstances, the fund will invest at least 80% of its total assets in component securities. The index and fund seek to provide exposure to the companies of the S&P 500® Index (the S&P 500®) with the exception of those companies included in the Financials and Real Estate Sectors.

Inception Date: 22/09/2015

Primary Benchmark: S&P 500 Ex-Financials & Real Estate USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.27%

Management Expense Ratio: 0.27 %

Market Stats

Unadjusted Closing Price

Adjusted Closing Price



Top Sectors


Top Regions


Valuation Growth & Performance

Share Volume

Relative Performance (Total Returns)

Relative Returns (From:    To: 2019-10-14 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SSO ProShares Ultra S&P500 0.90 %

-0.23 (-0.18%)

USD 2.40B
QLD ProShares Ultra QQQ 0.95 %

+0.09 (+0.09%)

USD 1.90B
UYG ProShares Ultra Financials 0.95 %

+0.08 (+0.17%)

USD 0.80B
PSQ ProShares Short QQQ 0.95 %

-0.01 (-0.04%)

USD 0.50B
DDM ProShares Ultra Dow30 0.95 %

-0.12 (-0.24%)

USD 0.36B
DOG ProShares Short Dow30 0.95 %

+0.05 (+0.09%)

USD 0.22B
UWM ProShares Ultra Russell2000 0.95 %

-0.46 (-0.73%)

USD 0.17B
DXD ProShares UltraShort Dow30 0.95 %

+0.06 (+0.23%)

USD 0.16B
MVV ProShares Ultra MidCap400 0.95 %

-0.29 (-0.74%)

USD 0.14B
URE ProShares Ultra Real Estate 0.95 %

-0.01 (-0.01%)

USD 0.14B

ETFs Containing SPXN

Symbol Name Weight Mer Price(Change) Market Cap


Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Capital Gain 19.25% 58% F 73% C
Dividend Return 0.81% 44% F 14% F
Total Return 20.06% 55% F 69% D+
Trailing 12 Months  
Capital Gain 3.92% 53% F 54% F
Dividend Return 1.14% 41% F 19% F
Total Return 5.06% 53% F 49% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.65% 66% D 77% C+
Dividend Return 1.15% 68% D+ 26% F
Total Return 9.80% 68% D+ 73% C
Risk Return Profile  
Volatility (Standard Deviation) 8.13% 89% B+ 79% C+
Risk Adjusted Return 120.61% 100% A+ 94% A
Market Capitalization 2.12M 13% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.